These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36159813)

  • 1. Non-coding RNA-mediated high expression of
    Chen K; Gong S; Fang X; Li Q; Ye M; Li J; Huang S; Zhao Y; Liu N; Li Y; Ma J
    Front Immunol; 2022; 13():920136. PubMed ID: 36159813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment.
    Ding Q; Lin F; Huang Z; Li Y; Cai S; Chen X; Liu H; Qiu S
    Sci Rep; 2024 Feb; 14(1):4426. PubMed ID: 38396056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of a competing endogenous RNA network in head and neck squamous cell carcinoma by pan-cancer analysis.
    Zheng D; Luo S; Wang S; Huang J; Zhou Y; Su L; Chen Z; Wang S; He W
    Transl Cancer Res; 2022 Sep; 11(9):3050-3063. PubMed ID: 36237258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CCND1-associated ceRNA network reveal the critical pathway of TPRG1-AS1-hsa-miR-363-3p-MYO1B as a prognostic marker for head and neck squamous cell carcinoma.
    Li Z; Qiu X; He Q; Fu X; Ji F; Tian X
    Sci Rep; 2023 Jul; 13(1):11831. PubMed ID: 37481637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXD1 expression in head and neck squamous carcinoma: a study based on TCGA, GEO and meta-analysis.
    Huang J; Liang B; Wang T
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34269372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
    Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT5E upregulation in head and neck squamous cell carcinoma: A novel biomarker on cancer-associated fibroblasts for predicting immunosuppressive tumor microenvironment.
    Chen XM; Liu YY; Tao BY; Xue XM; Zhang XX; Wang LL; Zhong H; Zhang J; Yang SM; Jiang QQ
    Front Immunol; 2022; 13():975847. PubMed ID: 36091055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast activation protein (FAP) as a prognostic biomarker in multiple tumors and its therapeutic potential in head and neck squamous cell carcinoma.
    Li R; Nan X; Li M; Rahhal O
    Oncol Res; 2024; 32(8):1323-1334. PubMed ID: 39055892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the Potential Correlation between Tumor Protein 73 and Head and Neck Squamous Cell Carcinoma.
    Chen Y
    Dis Markers; 2022; 2022():6410113. PubMed ID: 35756491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated analysis of diagnostic, prognostic value and potential drug treatment of GSDME in head and neck squamous cell carcinoma.
    Hu R; Lu M; She L
    Eur Arch Otorhinolaryngol; 2023 Sep; 280(9):4239-4253. PubMed ID: 37204444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CCR5 as a prognostic biomarker correlated with immune infiltrates in head and neck squamous cell carcinoma by bioinformatic study.
    Li C; Chen S; Liu C; Mo C; Gong W; Hu J; He M; Xie L; Hou X; Tang J; Ou M
    Hereditas; 2022 Sep; 159(1):37. PubMed ID: 36167571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signal peptidase complex catalytic subunit SEC11A upregulation is a biomarker of poor prognosis in patients with head and neck squamous cell carcinoma.
    Hu C; Fan J; He G; Dong C; Zhou S; Zheng Y
    PLoS One; 2022; 17(6):e0269166. PubMed ID: 35653344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical powers of Aminoacyl tRNA Synthetase Complex Interacting Multifunctional Protein 1 (AIMP1) for head-neck squamous cell carcinoma.
    Li Y; Liu H
    Cancer Biomark; 2022; 34(3):359-374. PubMed ID: 35068446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma.
    Shi C; Liu S; Tian X; Wang X; Gao P
    BMC Cancer; 2021 Sep; 21(1):1035. PubMed ID: 34530752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the molecular feature of M2 macrophages of head and neck squamous cell carcinoma.
    Wu S; Lv X; Wei H; Wu J; Liu S; Li X; Song J; Zou C; Ai Y
    J Cell Mol Med; 2024 Mar; 28(5):e18083. PubMed ID: 38393307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
    Sun K; Chen RX; Li JZ; Luo ZX
    Hereditas; 2022 Mar; 159(1):16. PubMed ID: 35241179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constructing a prognostic model for head and neck squamous cell carcinoma based on glucose metabolism related genes.
    Liu Y; Liu N; Zhou X; Zhao L; Wei W; Hu J; Luo Z
    Front Endocrinol (Lausanne); 2023; 14():1245629. PubMed ID: 37876534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spermine synthase (
    Pan X; Xue L; Sun Y
    Ann Transl Med; 2022 Nov; 10(22):1213. PubMed ID: 36544695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-methylome-derived epigenetic fingerprint as an immunophenotype indicator of durable clinical immunotherapeutic benefits in head and neck squamous cell carcinoma.
    Li R; Wen X; Lv RX; Ren XY; Cheng BL; Wang YK; Chen RZ; Hu W; Tang XR
    Cell Oncol (Dordr); 2024 Aug; 47(4):1129-1148. PubMed ID: 38315286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.